Literature DB >> 2782977

Erythrocyte sedimentation rate and C reactive protein in the assessment of polymyalgia rheumatica/giant cell arteritis on presentation and during follow up.

V Kyle1, T E Cawston, B L Hazleman.   

Abstract

The erythrocyte sedimentation rate (ESR) and C reactive protein (CRP) were measured in 74 patients with polymyalgia rheumatica (PMR)/giant cell arteritis (GCA) on presentation, in the first month of treatment, and at long term follow up (up to 177 weeks). Before treatment the ESR was raised (greater than 30 mm/h) in all cases and the CRP was raised (greater than 6 mg/l) in 49/55 cases. The ESR was a better indicator of clinical disease activity except in patients who felt completely well at week 1. 'False positive' increases of ESR or CRP were rare. During relapses ESR was normal in 37/77 (48%) of cases and CRP in 41/73 (56%). It is suggested that ESR is the most useful laboratory parameter in assessing PMR/GCA.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2782977      PMCID: PMC1003844          DOI: 10.1136/ard.48.8.667

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  18 in total

1.  TEMPORAL ARTERITIS.

Authors:  A G WHITFIELD; M BATEMAN; W T COOKE
Journal:  Br J Ophthalmol       Date:  1963-09       Impact factor: 4.638

2.  Erythrocyte sedimentation rate in elderly hospital in-patients.

Authors:  R V Boyd; B I Hoffbrand
Journal:  Br Med J       Date:  1966-04-09

3.  Erythrocyte sedimentation rate and age.

Authors:  G S Hayes; I N Stinson
Journal:  Arch Ophthalmol       Date:  1976-06

4.  Diurnal variation of erythrocyte sedimentation rate related to feeding.

Authors:  R K Mallya; H Berry; B E Mace; F C de Beer; M B Pepys
Journal:  Lancet       Date:  1982-02-13       Impact factor: 79.321

5.  C-reactive protein in giant cell (cranial, temporal) arteritis.

Authors:  J Eshaghian; J A Goeken
Journal:  Ophthalmology       Date:  1980-11       Impact factor: 12.079

6.  Giant cell arteritis. A five-year review of biopsy-proven cases in a teaching hospital.

Authors:  B Dare; E Byrne
Journal:  Med J Aust       Date:  1980-04-19       Impact factor: 7.738

7.  Temporal arteritis: a 25-year epidemiologic, clinical, and pathologic study.

Authors:  K A Huston; G G Hunder; J T Lie; R H Kennedy; L R Elveback
Journal:  Ann Intern Med       Date:  1978-02       Impact factor: 25.391

8.  Polymyalgia rheumatica: a 10-year epidemiologic and clinical study.

Authors:  T Y Chuang; G G Hunder; D M Ilstrup; L T Kurland
Journal:  Ann Intern Med       Date:  1982-11       Impact factor: 25.391

9.  Relationship of the erythrocyte sedimentation rate to acute phase proteins in polymyalgia rheumatica and giant cell arteritis.

Authors:  J R Park; J G Jones; B L Hazleman
Journal:  Ann Rheum Dis       Date:  1981-10       Impact factor: 19.103

10.  Development of giant cell (temporal) arteritis in a patient 'adequately' treated for polymyalgia rheumatica.

Authors:  R I Rynes; P Mika; L E Bartholomew
Journal:  Ann Rheum Dis       Date:  1977-02       Impact factor: 19.103

View more
  26 in total

1.  Giant Cell Arteritis.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2000-06

2.  Giant cell arteritis.

Authors:  V Kyle
Journal:  BMJ       Date:  1992-08-29

Review 3.  Recent advances in diagnostic strategies for giant cell arteritis.

Authors:  Tanaz A Kermani; Kenneth J Warrington
Journal:  Curr Neurol Neurosci Rep       Date:  2012-04       Impact factor: 5.081

4.  Disease Relapses among Patients with Giant Cell Arteritis: A Prospective, Longitudinal Cohort Study.

Authors:  Tanaz A Kermani; Kenneth J Warrington; David Cuthbertson; Simon Carette; Gary S Hoffman; Nader A Khalidi; Curry L Koening; Carol A Langford; Kathleen Maksimowicz-McKinnon; Carol A McAlear; Paul A Monach; Philip Seo; Peter A Merkel; Steven R Ytterberg
Journal:  J Rheumatol       Date:  2015-04-15       Impact factor: 4.666

Review 5.  Best practice in primary care pathology: review 2.

Authors:  W S Smellie; J O Forth; C A M McNulty; L Hirschowitz; D Lilic; R Gosling; D Bareford; E Logan; K G Kerr; G P Spickett; J Hoffman; A Galloway; C A Bloxham
Journal:  J Clin Pathol       Date:  2006-02       Impact factor: 3.411

6.  Treatment of polymyalgia rheumatica and giant cell arteritis.

Authors:  M T Watts; M E Nelson; I G Rennie
Journal:  Ann Rheum Dis       Date:  1990-07       Impact factor: 19.103

Review 7.  Neurology of the vasculitides and connective tissue diseases.

Authors:  P M Moore; B Richardson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-07       Impact factor: 10.154

8.  Development of a Core Set of Outcome Measures for Large-vessel Vasculitis: Report from OMERACT 2016.

Authors:  Antoine G Sreih; Fatma Alibaz-Oner; Tanaz A Kermani; Sibel Z Aydin; Peter F Cronholm; Trocon Davis; Ebony Easley; Ahmet Gul; Alfred Mahr; Carol A McAlear; Nataliya Milman; Joanna C Robson; Gunnar Tomasson; Haner Direskeneli; Peter A Merkel
Journal:  J Rheumatol       Date:  2017-09-01       Impact factor: 4.666

9.  The CRP initial response to treatment as prognostic factor in patients with polymyalgia rheumatica.

Authors:  S Schreiber; M Buyse
Journal:  Clin Rheumatol       Date:  1995-05       Impact factor: 2.980

10.  [Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) : solo or duet?].

Authors:  J G Kuipers; L Köhler
Journal:  Z Rheumatol       Date:  2013-06       Impact factor: 1.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.